Pfizer undeterred in CD47 plans as competitors face pitfalls With an eye on future pandemics, GSK will help set up 12 European countries for the possibility of an influenza pandemic The shape of things to come: DeepMind’s AlphaFold illuminates 3D structure of almost every protein known to science The NASH curse strikes again. Pfizer dumps early-stage asset for liver condition GV’s newest general partner, a psychiatrist and investor, wants to place ‘big bets’ in healthcare Takeda cuts ties to cancer drug landed in $120M Turnstone deal AbbVie's Allergan to pay out more than $2 billion to resolve opioid litigation: Bloomberg BD continues pharmacy tech shopping spree with $93M MedKeeper buy House overwhelmingly passes key telehealth extension bill Merck dodged billions in US taxes in offshoring Keytruda profits, Senate Democrats contend Bayer-Ionis' anti-thrombotic med doesn't increase bleeding in phase 2, setting stage for a new type of anticoagulant Linus Health debuts AI-powered early Alzheimer’s screening platform Teladoc takes hefty impairment charge in Q2 with losses mounting to nearly $10B Labcorp to splice off clinical development arm into standalone business Featured Story | By Max Bayer,Annalee Armstrong Pfizer is certain that its CD47 portfolio won't get gobbled up by the kind of clinical woes that have befallen its competitors. read more |
| |
|---|
|
Top Stories By Zoey Becker Living through COVID-19 has taught the industry and the public a lot about what it takes to manage a pandemic. Preparedness for future pandemics has become more front and center for governments around the globe. In that vein, GSK is helping 12 European countries prepare for a potential future influenza pandemic. read more By Conor Hale DeepMind's AI is helping researchers visualize the nearly 200 million proteins that form the basis of life for animals, plants, bacteria and more—spanning almost every organism on the planet that has had its genome sequenced. read more By James Waldron Another NASH drug bites the dust. This time it’s Pfizer’s early-stage asset danuglipron, which the drugmaker revealed this morning had been dumped for the liver condition. read more By Heather Landi GV, formerly Google Ventures, has deployed $1.3 billion into healthcare and life science companies since 2020. The VC firm's newest general partner, Ben Robbins, a psychiatrist and investor, sees opportunities to use GV’s deep pockets and Google’s tech capabilities to tackle some of the most entrenched problems in healthcare. read more By Nick Paul Taylor Takeda is walking away from a cancer prospect it picked up in a $120 million deal. In a pipeline clear-out that also hit narcolepsy candidate TAK-994, the Japanese drugmaker revealed it has returned the rights to oncolytic virus TAK-605 to Turnstone Biologics just 31 months after inking a deal for the drug. read more By Zoey Becker A day after Teva announced it will pay up to $4.25 billion to resolve nationwide opioid litigation, AbbVie's Allergan unit agreed to more than $2 billion to settle a consolidated litigation before a federal judge in Cleveland, according to people familiar with the matter, Bloomberg reports. read more By Andrea Park Making moves to bulk up its collection of high-tech pharmacy management tools is becoming a monthly thing for BD. read more By Robert King The House overwhelmingly passed legislation to extend key Medicare telehealth reimbursement flexibilities such as originating site through Dec. 2024. read more By Fraiser Kansteiner In recent years, Merck & Co. has dodged billions of dollars in U.S. taxes by offshoring profits on its immuno-oncology megablockbuster Keytruda, according to an ongoing investigation by Democrats on the Senate Finance Committee. read more By Annalee Armstrong Patients with kidney disease taking Ionis Pharmaceuticals and Bayer’s anti-thrombotic therapy did not experience an increase in major bleeding events as compared to those taking placebo, meaning patients may someday have a new anticoagulant option that does not come with a risk of bleeding. read more By Andrea Park Named for Charlie Brown’s blanket-toting best friend, Linus Health is aiming to become a trusted partner in early screening for Alzheimer’s disease and other dementias. read more By Heather Landi Telehealth giant Teladoc Wednesday reported a hefty loss of $3.1 billion in its second quarter. The company's share price tumbled in after-hours trading as management set lower expectations for its 2022 outlook. read more By Max Bayer Labcorp will spin off its clinical development arm into its own company, a departure from a decision at the end of 2021 to maintain the corporate structure. The deal is expected to close in the second half of next year. read more Resources Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 